Phase 1Terminated
Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma
A Phase I Dose Escalation Study of NMS-03597812, a PERK Inhibitor, in Adult Patients With Relapsed or Refractory Multiple Myeloma
- Sponsor
- Nerviano Medical Sciences (Industry)
- Enrolment
- 5 enrolled
- Conditions
- Multiple Myeloma
- Interventions
- NMS-03597812; NMS-03597812 + dexamethasone
- Ages
- adults, older adults
- Registry
- NCT05027594, EUCTR2020-004351-32
Full record on ClinicalTrials.gov
From the registry
This is a Phase I, first-in-human (FIH), open-label, non-randomized, multi-center study to explore the safety, tolerability, pharmacokinetics and preliminary antitumor activity of NMS-03597812 in adult patients with RRMM who have exhausted standard treatment options that are expected to provide meaningful clinical benefit or for whom standard therapy is considered unsuitable.
Primary outcomes
- Number of Participants with first-cycle dose limiting toxicity
History
Last registry update
Study completion
Primary completion
Started
Registered